Page last updated: 2024-08-24

aripiprazole and Psychoses

aripiprazole has been researched along with Psychoses in 298 studies

Research

Studies (298)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's125 (41.95)29.6817
2010's132 (44.30)24.3611
2020's41 (13.76)2.80

Authors

AuthorsStudies
Cui, H; Hu, Y; Li, C; Ling, Z; Tang, X; Tang, Y; Wang, J; Wei, Y; Xu, L; Zhang, T1
Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I1
Dragovic, M; Hacking, D; Hulme, D; Parmar, A; Shymko, G; Terina, G; Waters, F1
Correll, CU; Decara, MS; Fagerlund, B; Fink-Jensen, A; Galling, B; Jensen, KG; Jeppesen, P; Jepsen, JRM; Klauber, DG; Krogmann, A; Pagsberg, AK; Rudå, D; von Hardenberg, L1
Kim, SG; Seo, EH; Yang, HJ; Yoon, HJ1
Alisauskiene, R; Fathian, F; Fleichhacker, WW; Gjestad, R; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkevicute, I; Stabell, LA; Steen, VM1
Kam, O; Koola, MM; Lee, G; Reinfeld, S; Russell, G; Weiss, M1
Kashihara, K; Maeda, T; Yoshida, K1
Abler, VC; Demos, GN; Mahadik, BS; Rajagopalan, K; Rashid, N; Yunusa, I1
Chen, T; Gan, R; Hu, Y; Li, C; Raballo, A; Tang, X; Tang, Y; Wang, J; Wei, Y; Wu, G; Xu, L; Zeng, J; Zhang, T1
Di Lorenzo, G; Jannini, EA; Jannini, TB; Rossi, R; Sansone, A; Siracusano, A; Toscano, M1
Broberg, BV; Ebdrup, BH; Glenthøj, BY; Lykkesfeldt, J; Myken, AN; Nielsen, MØ; Skjerbæk, MW; Sørensen, ME1
Crespo-Facorro, B; Garrido-Torres, N; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J1
De Ronchi, D; Fabbri, C; Fanelli, G; Lippi, M; Serretti, A1
Ayesa-Arriola, R; Crespo-Facorro, B; Garrido-Sánchez, L; Gómez-Revuelta, M; Juncal-Ruiz, M; Mayoral-Van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Ruiz-Veguilla, M; Vázquez-Bourgon, J1
Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Lin, YT; Liu, CC; Liu, CM1
Ando, Y; Hisano, T; Kanamura, S; Maeda, K; Matsuzaka, Y; Morimoto, Y; Noguchi, M; Otsuka, T; Ozawa, H; Tanaka, D; Yamamoto, T1
Davies, SJ; Nutt, DJ; Zhou, C1
Bartolomei, G; Gambaro, E; Gramaglia, C; Lorenzini, L; Martelli, M; Zeppegno, P1
Acacio, MC; Dobson, L; Grace, T; Shymko, G; Tadier, S; Waters, F1
Bechdolf, A; de Millas, W; Falkai, P; Gaebel, W; Gallinat, J; Hasan, A; Heinz, A; Hellmich, M; Janssen, B; Juckel, G; Karow, A; Klosterkötter, J; Krüger-Özgürdal, S; Lambert, M; Maier, W; Meyer-Lindenberg, A; Müller, H; Pützfeld, V; Rausch, F; Schneider, F; Stützer, H; Wagner, M; Wobrock, T; Zink, M1
Dudek, D; Heitzman, J; Janas-Kozik, M; Remberk, B; Samochowiec, J; Słopień, A; Wichniak, A1
Abdel-Baki, A; Béchard, L; Brodeur, S; Corbeil, O; Demers, MF; Desmeules, C; Dorval, M; Essiambre, AM; Fournier, É; Giroux, I; Huot-Lavoie, M; Jacques, C; Roy, MA; Soulard, M; Thériault, C1
Juza, R; Kelemen, E; Korabecny, J; Petrasek, T; Soukup, O; Stuchlik, A; Tuckova, K; Vojtechova, I1
Iyo, M; Kanahara, N; Kimura, H; Kogure, M; Koyoshi, S; Nakata, Y; Oiwa, T; Saito, T; Sasaki, T; Yamasaki, F; Yanagisawa, Y; Yoshida, T1
Foreman, K; Loh, R; Thurstone, C; Thurstone, CA; Wolf, C1
Buckle, J; Forshall, E; Harris, M; Kavanagh, G; Murphy, T; Pereira, M; Thompson, A; Whale, R; Wilson, M1
Iyer, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Shah, J1
Garel, N; Joober, R1
Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J1
Shad, MU; Yeager, A1
Economou, M; Kontoangelos, K; Lazaratou, E; Papageorgiou, CC; Yiannopoulou, KG1
Crespo-Facorro, B; García-Rizo, C; González-Rodríguez, A; Labad, J; Monreal, JA; Montalvo, I; Palao, D1
Du, Y; Hard, M; Marandi, M; von Moltke, L; Walling, DP; Wehr, A; Weiden, PJ1
Dobson, L; Grace, T; Hacking, D; Jolly, N; Kapi, P; Parmar, A; Shymko, G; Waters, F1
Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J1
Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B1
Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S1
Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G1
Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J1
Carmichael, PH; Corbeil, O; Corbeil, S; Demers, MF; Dorval, M; Giroux, I; Jacques, C; Roy, MA1
Ayesa-Arriola, R; Crespo-Facorro, B; Ortiz-García de la Foz, V; Setién-Suero, E; Suárez-Pinilla, P1
Alba, L; Alonso, L; Coll, C; Ortiz, S; Palma, S; Pérez, H; Sáez, S; Vallés, V1
Baker, RA; Eramo, A; Hertel, P; Ismail, Z; Jin, N; Kane, JM; McQuade, RD; Miguelez, M; Perry, P; Peters-Strickland, T; Sanchez, R1
Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R1
Hard, ML; Mills, RJ; Sadler, BM; von Moltke, L; Wehr, AY; Weiden, PJ1
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JRM; Klauber, DG; Lange, T; Lauritsen, MG; Madsen, S; Nyvang, L; Pagsberg, AK; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Werge, TM; Winkel, P1
Bishop, JR; Brown, JT; Eum, S; Lee, AM; Schneiderhan, ME1
Nesvåg, R1
de Haan, L; Schulte, PFJ; Veerman, SRT1
Lee, C; Shen, YC1
Baker, RA; Carson, W; Correll, CU; Kohegyi, E; McQuade, R; Nyilas, M; Salzman, PM; Sanchez, R; Zhao, C1
Brunet, M; Espinosa-Martínez, L; Fortea, A; Fortuna, V; González-Rodríguez, A; Oriolo, G; Parellada, E1
Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J1
Correll, CU; Fagerlund, B; Fink-Jensen, A; Gärtner, S; Jensen, KG; Jepsen, JR; Juul, K; Klauber, DG; Pagsberg, AK; Rudå, D; Stentebjerg-Olesen, M1
Vohra, A1
Chan, CH; Chan, HY; Chen, YC1
Bramness, JG; Handal, M; Hartz, I; Hjellvik, V; Nesvåg, R; Skurtveit, S1
Baeza, I; de Castro, C; Espinosa, L; Fortea, A; Ilzarbe, D; Oriolo, G; Solerdelcoll, M; Sugranyes, G1
Aoki, S; Harada, T; Kishi, Y; Nomura, A; Sato, K; Takeda, T; Washida, K; Yada, Y; Yoshimura, B; Yoshimura, Y1
Gastaldon, C; Ostuzzi, G; Papola, D1
Barreto, S; Kar, N1
Bateman, BT; Cohen, JM; Cohen, LS; Desai, RJ; Glynn, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E1
Ballerini, A; Brugnoli, R; Carrus, D; Comparelli, A; De Filippis, S; Del Casale, A; Ducci, G; Francomano, A; Girardi, P; Kotzalidis, GD; Mancinelli, I; Marcellusi, A; Mennini, FS; Pompili, M; Rapinesi, C; Sani, G; Sorice, S; Splendori, F; Trovini, G; Verzura, C1
Adams, HA; Buchanan, RW; Buckley, PF; Dickerson, FB; Earl, AK; Feldman, SM; Hackman, AL; Kearns, AM; Kelly, DL; Koola, MM; Liu, F; Luttrell, SE; McEvoy, JP; McMahon, RP; Narang, S; Nichols, RB; Powell, MM; RachBeisel, JA; Richardson, CM; Sayer, MA; Sullivan, KM; Vyas, G; Wehring, HJ1
Crespo-Facorro, B; Juncal-Ruiz, M; Leza, JC; López-Hoyos, M; Martínez-Garcia, O; Ocejo-Viñals, JG; Ortiz-García de la Foz, V; Ramírez-Bonilla, M; Riesco-Dávila, L1
Ayesa-Arriola, R; Crespo-Facorro, B; Gimenez-Donoso, S; Setien-Suero, E; Tirapu-Ustarroz, J; Treen-Calvo, D1
Fryefield, K; Shad, MU1
Crespo-Facorro, B; Gómez-Revuelta, M; González-Pinto, A; Juncal-Ruiz, M; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J1
Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J1
Azorin, JM; Simon, N1
Gehrmann, J; Götz Lampe, P1
Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J1
Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L1
Kahn, DA1
Correll, CU; Decara, MS; Eriksson, F; Fagerlund, B; Fink-Jensen, A; Jensen, KG; Jepsen, JRM; Klauber, DG; Pagsberg, AK; Rudå, D1
Edelsohn, GA1
Haslemo, T; Ingelman-Sundberg, M; Jukic, MM; Molden, E; Smith, RL1
Cope, N; Fowler, JC; Knights, J; Makin, A; Peters-Strickland, T; Phiri, P; Rathod, S1
Chouinard, G; Peretti, CS1
Ayesa-Arriola, R; Crespo-Facorro, B; Mata, I; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM; Vázquez-Barquero, JL1
Edlinger, M; Fleischhacker, W; Hofer, A; Seppi, K1
Alnıak, İ; Ulusoy, S; Yavuz, KF1
Remington, G; Takeuchi, H1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Tang, CS; Wang, LJ; Yeh, CB1
Ayesa-Arriola, R; Crespo-Facorro, B; de la Foz, VO; Martinez-Garcia, O; Mata, I; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM1
Cho, DH; Chung, YC; Hahn, SW; Jeong, B; Kim, JH; Kim, SW; Koo, MS; Lee, SH; Lee, SJ; Lee, YH; Park, JI; Rho, SH1
Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD1
Alcera, E; Coffey, DB; Patel, S; Tosyali, PM; Varas, DB1
Gallego, JA; Ikuta, T; Kane, J; Malhotra, AK; Peters, BD; Robinson, DG; Szeszko, PR1
Eleméry, M; Faludi, G; Kovács, G; Szegő, A1
Eatt, J; Varghese, ST1
Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A1
Bruno, A; Muscatello, MR; Pandolfo, G; Romeo, VM; Scimeca, G; Zoccali, RA1
Makkos, Z1
Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JR; Juul, K; Klauber, DG; Lauritsen, MB; Madsen, S; Nyvang, L; Pagsberg, AK; Paludan, J; Pedersen, J; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Thomsen, PH; Vernal, DL; Werge, TM; Wetterslev, J; Winge, K1
Morrissette, DA; Stahl, SM1
Gentile, S1
Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R1
Argyelan, M; Gallego, JA; Ikuta, T; Kane, JM; Karlsgodt, K; Lencz, T; Malhotra, AK; Robinson, DG; Sarpal, DK; Szeszko, PR1
Calabrò, G; Caloro, M; Cuomo, I; De Filippis, S; Girardi, P; Kotzalidis, GD; Ranieri, V; Telesforo, CL; Zingaretti, P1
Jarvis, GE; Margolese, HC; Propst, AJ1
Connolly, JG; Schneeweiss, MC; Toomey, TJ1
Álamo, C; Bernardo, M; Bobes, J; Hidalgo, D; Murru, A; Saiz-Ruiz, J; Vieta, E1
Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK1
Addington, J; Gallego, JA; John, M; Kane, JM; Lencz, T; Malhotra, AK; Robinson, DG; Tohen, M; Yu, J; Zhang, JP1
Addington, J; Bennett, N; Braga, RJ; Correll, CU; Gallego, JA; Greenberg, J; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Lopez, L; Malhotra, AK; Naraine, M; Petrides, G; Robinson, DG; Sevy, SM; Tohen, M; Zhang, JP1
Arango, C1
Addington, J; Burdick, KE; DeRosse, P; Gallego, JA; Goldberg, TE; Hassoun, Y; John, M; Kane, JM; Kellner, CH; Lencz, T; Malhotra, AK; Petrides, G; Robinson, DG; Tohen, M; Trampush, JW; Zhang, JP1
De Risio, L; Di Nicola, M; Fasano, A; Janiri, L; Martinotti, G; Pettorruso, M1
Ahn, J; Joe, S; Lim, J; Park, C; Park, J1
Chan, HY; Chen, WJ; Hsieh, MH; Hwang, TJ; Hwu, HG; Kuo, CH; Lin, CF; Liu, CC; Liu, CM; Lo, WM1
Prommer, E1
Aitchison, KJ; Heald, AH; Lodhi, RJ; Malik, A; Masand, S; McAllister, VD; O'Keane, V; Sherwood, RA; Shivakumar, K; Young, LC1
Aggarwal, A; Gopalakrishna, G; Lauriello, J1
Abadi, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Rho, A1
Bruhn, CH; Fink-Jensen, A; Jakobsen, KD; Nielsen, J; Pagsberg, AK1
Cocker, KE; Reese, TR; Thiel, DJ1
Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M1
Du, Y; Jamal, HH; Pendergrass, JC; Risinger, R; Silverman, BL; Targum, SD1
Chen, YW; Tseng, PT1
Mahapatra, A; Sagar, R; Sharma, P1
Gallego, JA; Malhotra, AK; Rhindress, K; Robinson, DG; Szeszko, PR; Wellington, R1
Amado-Señaris, JA; Ayesa-Arriola, R; Correll, C; Crespo-Facorro, B; Labad, J; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Teresa Garcia-Unzueta, M; Valdizan, EM1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Glikman, J; Krebs, MO; Limosin, F; Millet, B1
Sikich, L1
Breder, CD; Carson, WH; Marcus, R; McQuade, R; Porsteinsson, AP; Streim, JE; Swanink, R1
Tsai, AC1
Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M1
Gründer, G; Sheldrick, AJ1
Carlat, D1
Ibe, AI; Lee, JH; Makhzoumi, ZH; McLean, LP1
Chou, YH; Lin, WC1
Choi, JS; Jang, IJ; Kang, DH; Kim, E; Kwon, JS; Shin, SG; Yu, KS1
Azzoni, A; Raja, M1
Nakaya, M; Ohmori, K1
Coffey, BJ; Groff, K1
Madhusoodanan, S; Shah, P1
Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R1
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R1
Bledowski, J; Kahn, DA; Pandurangi, A; Trutia, A1
Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO1
Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY1
Chang, CC; Chen, SH; Hsu, WY1
Kyomen, HH; Whitfield, TH1
Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD1
Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV1
Bueno, JR; Campos, JA; Chaves, A; de Abreu, PB; de Matos E Souza, FG; de Oliveira, IR; de Sena, EP; E Silva, JA; Elkis, H; Gattaz, WF; Louzã, MR1
Adan-Manes, J; Garcia-Parajua, P1
Bashir, M; Keith, S; MacRae, A; Majjiga, C; Murphy, J; Shajahan, P; Taylor, M1
Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM1
Pae, CU1
Kumar, R; Sachdev, PS1
Kalapatapu, RK; Schimming, C1
Chung, S; Jeon, YW; Jeong, B; Jun, TY; Jung, HY; Kim, CE; Kim, CY; Kim, DH; Kwon, JS; Lee, JN; Lee, MS1
Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R1
Kalapatapu, RK1
Huang, YC; Lee, Y; Lin, PY1
Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E1
Mace, S; Taylor, D1
Kashima, H; Kobayashi, H; Koshikawa, H; Mizuno, M; Morita, K; Takeshi, K; Yamazawa, R1
Chen, YJ; Hsueh, WC; Liao, KC; Lin, KH; Lin, YT; Lu, CL; Yen, MH1
Bat-Pitault, F; Delorme, R1
Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E1
Leckband, SG; Meyer, JM; Strack, DK1
Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV1
McIntyre, RS1
Stip, E; Tourjman, V1
Chou, JC1
Audino, B; Curtis, J; Donohue, AM; Filymer, DM; Finkel, N; Josiassen, RC; Kacso, M; Shaughnessy, RA; Skuban, N1
Barth, KS; Garner, A; Phan, SV; Snarr, BS; VandenBerg, AM1
Manoj, P; Skopek, M1
Hwu, HG; Lai, MC; Liu, CC; Sheu, YH; Wu, SY1
Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K1
Chi, CH; Hsieh, PH; Hwang, KS; Lin, CE; Tzeng, NS1
Fleischhacker, WW; Hoertnagl, C; Hofer, A; Pfaffenberger, N1
Remington, G1
Kapur, S; Patel, MX; Sparshatt, A; Taylor, D1
Konstantakopoulos, G; Kouzoupis, AV; Mourikis, I; Oulis, P; Papageorgiou, SG1
Chou, YH; Wang, SJ; Wu, CL; Yang, KC1
Chen, CH; Chiu, YH; Lu, ML1
Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R1
Correll, CU1
Gumus, S; Kamberyan, K; Saatcioglu, O; Yanik, M1
Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M1
Kobayashi, T1
Alexander, J; Lecamwasam, DL1
Bang, L; Harris, TB; Mian, A; Muscal, E1
Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS1
de Arce Cordón, R; Eding, E; Marques-Teixeira, J; Milanova, V; Rancans, E; Schreiner, A1
Bechdolf, A; Brüne, M; de Millas, W; Gaebel, W; Heinz, A; Janssen, B; Klosterkötter, J; Krüger-Özgürdal, S; Lambert, M; Lautenschlager, M; Maier, W; Michel, TM; Müller, H; Naber, D; Riedel, M; Schneider, F; Stützer, H; Wagner, M; Wobrock, T1
Weiden, PJ1
Babu, GN; Chandra, P; Kumar, R; Saddichha, S1
Ikeda, R; Katagiri, N; Mizumura, S; Mizuno, M; Nemoto, T; Shiraga, N; Tohgi, N; Tsujino, N; Yamaguchi, T1
Ishitobi, M; Kosaka, H; Murata, T; Oonuma, M; Takahashi, T; Wada, Y1
Brotzge, K; El-Mallakh, RS; Manshadi, M1
Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H1
Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K1
Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S1
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C1
Andrade, C; Chittaranjan, AC; Mendhekar, DN1
Hon, A1
Doey, T1
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D1
Nasti, JJ1
Chen, CK; Chou, MC; Chou, WJ; Huang, YS; Liang, HY; Tang, CS; Wang, LJ; Wu, YY; Yeh, CB1
Bradshaw, B; Henry, J; Macedo, LR; Marino, J1
Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ1
Adams, CE; Jones, H; Powney, MJ1
Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA1
Chien, YL; Hsieh, MH; Hwang, TJ; Hwu, HG; Liu, CC; Liu, CM1
Anttila, E; Lahti, A; Räsänen, P; Riala, K1
Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M1
De Deyn, PP; Drenth, AF; Kremer, BP; Oude Voshaar, RC; Van Dam, D1
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL1
Ali, M; Iwamoto, T; Kaplita, S; Marcus, R; Marder, SR; McQuade, RD; Safferman, AZ; Saha, A; Stock, E1
Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J1
Duggal, HS1
Argo, TR; Carnahan, RM; Perry, PJ1
Green, B1
Lieberman, JA1
Petty, F; Praveen, F; Ramaswamy, S; Sattar, SP; Vijay, D; William, M1
Crismon, ML; DeLeon, A; Patel, NC1
Mack, JE; Reeves, RR1
Perry, CM; Swainston Harrison, T1
Davids, E; Fischer, B; Gastpar, M1
Bowers, MB; Cooper, C; Lim, S; Pralea, C; Schnitt, J1
Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Reddy, H1
Finkel, S1
Katz, IR1
Cheney, EM; DeQuardo, JR; Sajbel, TA1
Bark, N; Citrome, L; Josiassen, R; Mallikaarjun, S; Salazar, DE1
Barzman, DH; Campbell, P; DelBello, MP; Delgado, SV; Fleck, DE; Gernert, B; Kowatch, RA; Pathak, S; Rappaport, K; Strakowski, SM1
Errico, JR; Yates, WR1
DeQuardo, JR1
Beard, L; Brown, ES; Garza, M; Jeffress, J; Liggin, JD1
Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA1
Ball, MP; Cates, ME; Hooper, ET; Skipwith, DF1
Breder, C; Carson, WH; De Deyn, P; Iwamoto, T; Jeste, DV; Kostic, D; Swanink, R1
Fricchione, GL; Huffman, JC1
Baldessarini, RJ; Grant, MJ1
Scholten, MR; Selten, JP1
Minervini, L; Romano, M; Ruffatti, A; Sonino, N1
Engelhardt, E; Laks, J; Marinho, V; Miotto, R1
Barnas, ME; Hussain, N; Petrides, G1
Howland, RH1
Folnegović-Smalc, V; Kozumplik, O; Mimica, N; Uzun, S1
Carson, WH; Citrome, L; Czobor, P; Hardy, S; Kostic, D; Marcus, R; McQuade, RD; Volavka, J1
Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD1
Aderhold, V; Haasen, C; Lambert, M; Reimer, J1
Ballard, C; Waite, J1
Calliess, IT; Kropp, S; Sieberer, M; Ziegenbein, M1
Crandall, DT; Iwamoto, T; Kostic, D; Marcus, RN; McQuade, RD; Nyilas, M; Pans, M; Riera, LC; Stock, EG; Tandon, R1
Raja, M1
Arends, J; Slooff, CJ1
Beers, E; Loonen, AJ; Van Grootheest, AC1
Blashki, G; Keks, N1
Hara, C; Rocha, FL1
Clarke, LA; Kaushik, S; Lindenmayer, JP1
Andrade, C; Mendhekar, DN; Sunder, KR1
Ali, IM; Morris, HR; Wickremaratchi, M1
Alla, L; Sabaratnam, M; Shastri, M1
Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E1
Balhara, YP; Kayal, M; Varghese, ST1
Berman, RM; Carson, WH; Factor, SA; Friedman, JH; Goetz, CG; Marcus, RN; Ondo, WG; Wojcieszek, J1
Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE1
De Oliveira, IR; Juruena, MF1
Chen, CH; Haw-Ming, L; Lin, CC; Shen, YC1
Arlien-Soborg, P; Kondziella, D1
Padala, PR; Petty, F; Wengel, SP1
Citrome, L; Jaffe, A; Levine, J1
Chan, HY; Chiang, SC; Hwang, TJ; Hwu, HG; Lin, SK; Lin, WW; Su, TP1
Auby, P; Marcus, RN; McQuade, RD; Oren, DA; Sack, DA; Tran-Johnson, TK1
Gründer, G; Hiemke, C; Kircher, T; Leube, D; Schlotterbeck, P1
Brunelle, J; Gouin, P; Guigueno, S; Tamion, F; Thibaut, F1
Alici-Evcimen, Y; Basil, B; Evcimen, H; Gorman, JM; Mania, I; Mathews, M1
Boulton, DW; Citrome, L; Macher, JP; Mallikaarjun, S; Salazar, DE1
Das, A; Desarkar, P; Nizamie, SH1
Bowers, MB; Lim, S1
Ahuja, N; Lloyd, AJ1
Allen, MH; Crandall, DT; Currier, GW; Daniel, DG; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL1
Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM1
Hurtig, HI; Weintraub, D1
Breder, CD; Forbes, A; Marcus, RN; McQuade, RD; Mintzer, JE; Swanink, R; Tune, LE1
Lu, JS; Pierre, JM1
Delgado, SV; Strawn, JR1
Aragona, M1
Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M1
Faruqui, RA; Zaidi, SH1
Aydemir, MC; Goka, E; Kisa, C; Yalcin, DO1
Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ1
Dale, R; Varkula, M1
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M1
Englisch, S; Zink, M1
Stahl, SM2
Dorado, P; Llerena, A; López-Torres, E; Peñas-Lledó, E; Salomón, J; Vicario, F1

Reviews

52 review(s) available for aripiprazole and Psychoses

ArticleYear
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
    The journal of prevention of Alzheimer's disease, 2021, Volume: 8, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Dementia; Humans; Olanzapine; Psychotic Disorders; Risperidone

2021
Aripiprazole in young people with early psychosis: a systematic review and meta-analysis of weight gain.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2022, Volume: 30, Issue:1

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Weight Gain

2022
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
    Advances in therapy, 2022, Volume: 39, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Humans; Network Meta-Analysis; Off-Label Use; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Treatment Outcome

2022
Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:9

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Male; Psychotic Disorders; Risperidone; Sexual Dysfunction, Physiological

2022
The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
    International clinical psychopharmacology, 2022, 11-01, Volume: 37, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Humans; Polypharmacy; Psychotic Disorders; Quinolones; Thiophenes

2022
Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
    Schizophrenia research, 2020, Volume: 222

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hyperprolactinemia; Prolactin; Psychotic Disorders

2020
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
    Drug and alcohol dependence, 2021, 02-01, Volume: 219

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia

2021
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
    The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention

2021
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.
    Drugs, 2017, Volume: 77, Issue:13

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Humans; Meta-Analysis as Topic; Psychotic Disorders; Quality of Life; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology

2017
[Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    L'Encephale, 2018, Volume: 44, Issue:6

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Psychotic Disorders; Schizophrenia

2018
A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.
    Psychopharmacology, 2013, Volume: 228, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Practice Guidelines as Topic; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology

2013
Atypical antipsychotics for psychosis in adolescents.
    The Cochrane database of systematic reviews, 2013, Oct-15, Issue:10

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia

2013
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
    CNS spectrums, 2014, Volume: 19, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence

2014
A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:12

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Postpartum Period; Pregnancy; Psychotic Disorders; Quinolones; Schizophrenia

2014
Antipsychotic switching in schizoaffective disorder: A systematic review.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2016, Volume: 17, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Drug Substitution; Humans; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Risperidone; Thiazoles

2016
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
    International journal of psychiatry in medicine, 2015, Volume: 49, Issue:1

    Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology

2015
Aripiprazole.
    The American journal of hospice & palliative care, 2017, Volume: 34, Issue:2

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Delirium; Humans; Psychotic Disorders

2017
Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Clinical schizophrenia & related psychoses, 2016,spring, Volume: 10, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Psychotic Disorders; Schizophrenia; United States

2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
    American family physician, 2016, Aug-15, Volume: 94, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; Benzodiazepines; Cognitive Behavioral Therapy; Dementia; Emotions; Humans; Hypotension, Orthostatic; Metabolic Syndrome; Neuroleptic Malignant Syndrome; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Risperidone

2016
A Review of Differences in Clinical Characteristics between Tardive Syndrome Induced or Improved by Aripiprazole Treatment.
    Acta neurologica Taiwanica, 2016, Sep-15, Volume: 25, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dystonia; Humans; Parkinson Disease, Secondary; Psychotic Disorders; Tardive Dyskinesia

2016
[Present data and treatment schedule of aripiprazole in the treatment of schizophrenia].
    L'Encephale, 2008, Volume: 34, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
    The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 4

    Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure

2008
Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.
    Clinical interventions in aging, 2008, Volume: 3, Issue:3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2008
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult

2009
Akathisia and second-generation antipsychotic drugs.
    Current opinion in psychiatry, 2009, Volume: 22, Issue:3

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles

2009
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder.
    CNS drugs, 2009, Volume: 23, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia

2009
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2010
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Clinical therapeutics, 2010, Volume: 32 Suppl 1

    Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult

2010
Mixed episodes with psychotic features.
    CNS spectrums, 2009, Volume: 14, Issue:11 Suppl 1

    Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evidence-Based Medicine; Hospitalization; Humans; Male; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Treatment Outcome; Valproic Acid

2009
Antipsychotics in pregnancy.
    Journal of psychiatric and mental health nursing, 2010, Volume: 17, Issue:2

    Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles

2010
A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Quinolones; Receptors, Dopamine; Treatment Outcome

2010
Switching and combining antipsychotics.
    CNS spectrums, 2010, Volume: 15, Issue:4 Suppl 6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain

2010
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
    Journal of psychiatric practice, 2012, Volume: 18, Issue:1

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2012
Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review.
    Journal of affective disorders, 2012, Volume: 138 Suppl

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2012
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
    Journal of sex & marital therapy, 2012, Volume: 38, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents

2012
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
    The Cochrane database of systematic reviews, 2012, Nov-14, Volume: 11

    Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles

2012
Aripiprazole in the treatment of Alzheimer's disease.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:4

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Meta-Analysis as Topic; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine; Serotonin 5-HT2 Receptor Antagonists

2013
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
    Schizophrenia research, 2003, Jun-01, Volume: 61, Issue:2-3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology

2003
Focus on aripiprazole.
    Current medical research and opinion, 2004, Volume: 20, Issue:2

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2004
Dopamine partial agonists: a new class of antipsychotic.
    CNS drugs, 2004, Volume: 18, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin; Treatment Outcome

2004
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
    Clinical therapeutics, 2004, Volume: 26, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia

2004
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Drugs, 2004, Volume: 64, Issue:15

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Schizophrenia; Tissue Distribution; Treatment Outcome

2004
[Aripiprazole: a new atypical antipsychotic drug].
    Fortschritte der Neurologie-Psychiatrie, 2004, Volume: 72, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic

2004
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:12 Suppl

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States

2004
Optimizing atypical antipsychotic treatment strategies in the elderly.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:12 Suppl

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome

2004
Aripiprazole: an overview of a novel antipsychotic.
    Psychiatria Danubina, 2005, Volume: 17, Issue:1-2

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Brain; Clinical Trials as Topic; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Psychotic Disorders; Quinolones; Receptors, Neurotransmitter; Treatment Outcome

2005
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Double-Blind Method; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2005
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1

    Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone

2006
Treatment of psychosis: 30 years of progress.
    Journal of clinical pharmacy and therapeutics, 2006, Volume: 31, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles

2006
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
    The American journal of psychiatry, 2007, Volume: 164, Issue:10

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones

2007
Combined antipsychotic treatment involving clozapine and aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Aug-01, Volume: 32, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Weight Loss

2008
Aripiprazole. Abilitat, OPC 14597.
    Drugs in R&D, 2002, Volume: 3, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine D2 Receptor Antagonists; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2

2002

Trials

72 trial(s) available for aripiprazole and Psychoses

ArticleYear
Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2022, Volume: 61, Issue:8

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Female; Humans; Male; Predictive Value of Tests; Psychotic Disorders; Quetiapine Fumarate; Treatment Outcome

2022
Association between C-reactive protein levels and antipsychotic treatment during 12 months follow-up period after acute psychosis.
    Schizophrenia research, 2022, Volume: 241

    Topics: Antipsychotic Agents; Aripiprazole; C-Reactive Protein; Follow-Up Studies; Humans; Psychotic Disorders

2022
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.
    The international journal of neuropsychopharmacology, 2022, 10-25, Volume: 25, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Lipids; Metabolome; Psychoses, Substance-Induced; Psychotic Disorders; Risperidone

2022
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial.
    The international journal of neuropsychopharmacology, 2022, 11-17, Volume: 25, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; Treatment Outcome

2022
Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT).
    Schizophrenia bulletin, 2023, 07-04, Volume: 49, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Humans; Knowledge; Psychotic Disorders; Treatment Outcome

2023
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
    The Journal of clinical psychiatry, 2019, 08-27, Volume: 80, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Weight Gain; Young Adult

2019
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
    The international journal of neuropsychopharmacology, 2020, 04-23, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult

2020
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    CNS drugs, 2020, Volume: 34, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Treatment Outcome

2020
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2020, Volume: 39

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult

2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    The lancet. Psychiatry, 2020, Volume: 7, Issue:11

    Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Norway; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult

2020
Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2021, Volume: 47

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Prospective Studies; Psychotic Disorders; Risperidone; Treatment Outcome

2021
Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison.
    Progress in neuro-psychopharmacology & biological psychiatry, 2021, 08-30, Volume: 110

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition; Cognition Disorders; Cohort Studies; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Psychotic Disorders; Risperidone; Time Factors; Young Adult

2021
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia

2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
    Psychopharmacology, 2017, Volume: 234, Issue:17

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult

2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    CNS drugs, 2017, Volume: 31, Issue:7

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Models, Biological; Psychotic Disorders; Schizophrenia

2017
Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    The lancet. Psychiatry, 2017, Volume: 4, Issue:8

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain

2017
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2017, Volume: 56, Issue:9

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia

2017
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
    Psychopharmacology, 2018, Volume: 235, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult

2018
Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
    Psychopharmacology, 2018, Volume: 235, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Male; Psychotic Disorders; Quetiapine Fumarate

2018
Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:4

    Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Drug Therapy, Combination; Female; Galactorrhea; Humans; Medication Adherence; Oligomenorrhea; Premenopause; Prolactin; Psychotic Disorders; Quality of Life

2018
Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals: A 3 months randomized study.
    Schizophrenia research, 2018, Volume: 202

    Topics: Adult; Anti-Inflammatory Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Cytokines; Female; Humans; Longitudinal Studies; Male; Psychotic Disorders; Risperidone; Treatment Outcome

2018
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
    The international journal of neuropsychopharmacology, 2018, 12-01, Volume: 21, Issue:12

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult

2018
Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients.
    Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 2019, Volume: 47, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Germany; Humans; Psychotic Disorders

2019
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children
    Journal of the American Academy of Child and Adolescent Psychiatry, 2019, Volume: 58, Issue:11

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain

2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.
    BMJ open, 2019, 06-27, Volume: 9, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical Informatics Applications; Medication Adherence; Mobile Applications; Multicenter Studies as Topic; Olanzapine; Pragmatic Clinical Trials as Topic; Psychiatry; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Tablets; United Kingdom

2019
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
    Schizophrenia research, 2013, Volume: 147, Issue:2-3

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Outcome Assessment, Health Care; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Thiazoles; Time Factors; Young Adult

2013
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
    Psychopharmacology, 2014, Volume: 231, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Treatment Outcome; Young Adult

2014
The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
    International clinical psychopharmacology, 2014, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Republic of Korea; Treatment Outcome; Young Adult

2014
White matter changes associated with antipsychotic treatment in first-episode psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:6

    Topics: Anisotropy; Antipsychotic Agents; Aripiprazole; Brain; Diffusion Tensor Imaging; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipoproteins, LDL; Longitudinal Studies; Male; Nerve Fibers, Myelinated; Occipital Lobe; Parietal Lobe; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Young Adult

2014
Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study.
    Substance abuse, 2014, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Drug Therapy, Combination; Female; Fructose; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Topiramate; Treatment Outcome; Young Adult

2014
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
    BMC psychiatry, 2014, Jul-11, Volume: 14

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Patient Selection; Piperazines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Quinolones; Sample Size; Schizophrenia

2014
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
    Schizophrenia research, 2014, Volume: 159, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain

2014
Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.
    JAMA psychiatry, 2015, Volume: 72, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cerebral Cortex; Connectome; Corpus Striatum; Drug Monitoring; Episode of Care; Female; Humans; Magnetic Resonance Imaging; Male; Neural Pathways; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Treatment Outcome

2015
A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Schizophrenia bulletin, 2015, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult

2015
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Schizophrenia bulletin, 2015, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Remission Induction; Risperidone; Schizophrenia; Young Adult

2015
Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Treatment Outcome

2015
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
    Psychopharmacology, 2016, Volume: 233, Issue:23-24

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult

2016
Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia.
    Schizophrenia research, 2017, Volume: 179

    Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Sex Factors; Young Adult

2017
Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
    Psychological medicine, 2017, Volume: 47, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dentate Gyrus; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Psychotic Disorders; Risperidone; Young Adult

2017
Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
    Schizophrenia research, 2017, Volume: 189

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cohort Studies; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Sex Characteristics; Thiazoles; Time Factors; Young Adult

2017
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2008, Volume: 16, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Behavioral Symptoms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nursing Homes; Piperazines; Psychotic Disorders; Quinolones; United States

2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:7

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides

2008
Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:12

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Young Adult

2008
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
    Psychiatria Danubina, 2008, Volume: 20, Issue:3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome

2008
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Schizophrenia research, 2009, Volume: 107, Issue:2-3

    Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult

2009
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol.
    CNS spectrums, 2009, Volume: 14, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2009
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome

2009
A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    International clinical psychopharmacology, 2009, Volume: 24, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Dopamine Antagonists; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Severity of Illness Index

2009
Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:5

    Topics: Adolescent; Adult; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Thinking; Treatment Outcome; Young Adult

2009
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Headache; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome

2009
Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
    Early intervention in psychiatry, 2010, Volume: 4, Issue:1

    Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Time Factors

2010
[Efficacy of aripiprazole on patients with at-risk mental state and subjective well-being].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2010, Volume: 112, Issue:11

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Personal Satisfaction; Piperazines; Psychotic Disorders; Quinolones; Risk; Young Adult

2010
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    The American journal of psychiatry, 2011, Volume: 168, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides

2011
Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).
    European archives of psychiatry and clinical neuroscience, 2012, Volume: 262, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Secondary Prevention; Time Factors

2012
Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosi
    Schizophrenia bulletin, 2011, Volume: 37 Suppl 2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Early Medical Intervention; Female; Humans; Male; Piperazines; Placebos; Psychotic Disorders; Quinolones; Treatment Outcome; Young Adult

2011
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss

2012
Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: comparison of first-episode to recurrent psychosis.
    Early intervention in psychiatry, 2013, Volume: 7, Issue:1

    Topics: Adolescent; Adolescent Behavior; Adult; Aripiprazole; Child; Female; Humans; Male; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Recurrence; Schizophrenia; Schizophrenic Psychology

2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States

2013
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome

2002
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Archives of general psychiatry, 2003, Volume: 60, Issue:7

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome

2003
Aripiprazole, a novel atypical antipsychotic drug.
    Pharmacotherapy, 2004, Volume: 24, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Forecasting; Humans; Piperazines; Psychotic Disorders; Quinolones

2004
Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Dopamine Agonists; Female; Humans; Male; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substance-Related Disorders; Treatment Outcome

2005
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
    Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones

2005
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
    Acta psychiatrica Scandinavica, 2006, Volume: 113, Issue:2

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides

2006
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
    Schizophrenia research, 2006, Volume: 84, Issue:1

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Piperazines; Primary Health Care; Prospective Studies; Psychiatry; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2006
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Psychopharmacology, 2006, Volume: 188, Issue:3

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment

2006
Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Treatment Outcome

2007
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Treatment Outcome

2007
Pharmacokinetics of aripiprazole and concomitant carbamazepine.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2007
Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Journal of psychiatric practice, 2007, Volume: 13, Issue:3

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia

2007
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    The American journal of psychiatry, 2007, Volume: 164, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome

2007
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2007, Volume: 15, Issue:11

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Institutionalization; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Severity of Illness Index; Treatment Outcome

2007

Other Studies

174 other study(ies) available for aripiprazole and Psychoses

ArticleYear
Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
    European archives of psychiatry and clinical neuroscience, 2022, Volume: 272, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Prodromal Symptoms; Psychotic Disorders; Risk Factors

2022
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
    BMC psychiatry, 2022, 01-29, Volume: 22, Issue:1

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benztropine; Female; Humans; Hyperprolactinemia; Prolactin; Propranolol; Psychomotor Agitation; Psychotic Disorders; Young Adult

2022
Case series on aripiprazole and dopamine supersensitivity psychosis.
    International clinical psychopharmacology, 2022, 05-01, Volume: 37, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Humans; Psychotic Disorders; Schizophrenia

2022
Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial.
    Neuropsychopharmacology reports, 2022, Volume: 42, Issue:2

    Topics: Activities of Daily Living; Aripiprazole; Hallucinations; Humans; Parkinson Disease; Psychotic Disorders

2022
Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
    The Journal of clinical psychiatry, 2022, 03-21, Volume: 83, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Humans; Male; Psychotic Disorders; Risk Assessment; Risperidone

2022
Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis.
    The international journal of neuropsychopharmacology, 2022, 08-16, Volume: 25, Issue:8

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Ascorbic Acid; Female; Humans; Psychotic Disorders; Schizophrenia; Young Adult

2022
The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis.
    Psychiatry research, 2022, Volume: 316

    Topics: Aripiprazole; Complement C4a; Complement C4b; Enzyme-Linked Immunosorbent Assay; Humans; Psychotic Disorders

2022
Combination therapy of modified electroconvulsive therapy and long-acting injectable aripiprazole for dopamine supersensitivity psychosis: a case report.
    Neurocase, 2022, Volume: 28, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Electroconvulsive Therapy; Humans; Male; Psychotic Disorders

2022
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.
    Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Butyrophenones; Chlorpromazine; Dopamine; Dopamine Agonists; Histamine; Humans; Psychotic Disorders; Railroads; Receptors, Dopamine D2; Systematic Reviews as Topic

2022
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report.
    Journal of psychiatric practice, 2022, 09-01, Volume: 28, Issue:5

    Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Delusions; Haloperidol; Humans; Male; Psychotic Disorders

2022
Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
    Schizophrenia research, 2023, Volume: 251

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections; Psychotic Disorders; Schizophrenia

2023
Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia.
    Psychiatria polska, 2022, Aug-31, Volume: 56, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Poland; Psychotic Disorders; Schizophrenia

2022
Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort study.
    BMC psychiatry, 2023, 04-25, Volume: 23, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Gambling; Humans; Multicenter Studies as Topic; Prospective Studies; Psychotic Disorders; Young Adult

2023
Dopaminergic and glutamatergic models of psychosis show differential sensitivity to aripiprazole and a novel experimental compound modulating D
    Progress in neuro-psychopharmacology & biological psychiatry, 2023, 12-20, Volume: 127

    Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Psychotic Disorders; Quinolones; Rats; Receptors, Serotonin

2023
Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice.
    Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Agonists; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia

2023
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
    Journal of child and adolescent psychopharmacology, 2023, Volume: 33, Issue:8

    Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; Program Evaluation; Psychotic Disorders; Retrospective Studies; Risperidone; Substance-Related Disorders

2023
Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
    Schizophrenia research, 2023, Volume: 261

    Topics: Antipsychotic Agents; Aripiprazole; Hospitalization; Humans; Olanzapine; Psychotic Disorders; Retrospective Studies

2023
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiency
    Journal of psychiatry & neuroscience : JPN, 2019, Nov-01, Volume: 44, Issue:6

    Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Delusions; Dystonia; Female; Hallucinations; Humans; Hypnotics and Sedatives; Intellectual Disability; Lorazepam; Loxapine; Olanzapine; Paranoid Disorders; Psychotic Disorders; Quetiapine Fumarate; Tourette Syndrome

2019
Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
    The primary care companion for CNS disorders, 2020, Jan-30, Volume: 22, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Psychotic Disorders; Retrospective Studies; Schizophrenia

2020
Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.
    Psychopharmacology bulletin, 2020, 03-12, Volume: 50, Issue:1

    Topics: Adolescent; Aripiprazole; Child; DiGeorge Syndrome; Hallucinations; Humans; Male; Psychotic Disorders; Schizophrenia

2020
Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
    Early intervention in psychiatry, 2021, Volume: 15, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Weight Gain

2021
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.
    CNS drugs, 2021, Volume: 35, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Behavior Rating Scale; Canada; Case-Control Studies; Causality; Female; Gambling; Humans; Male; Personality Assessment; Psychopathology; Psychotic Disorders; Risk Adjustment; Risk Assessment; Risk Factors

2021
New-onset psychosis: A case report of brief psychosis related to COVID-19 infection.
    Psychiatry research, 2021, Volume: 301

    Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; COVID-19; Diazepam; Humans; Male; Psychotic Disorders; SARS-CoV-2; Treatment Outcome

2021
Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    BMC psychiatry, 2017, 07-03, Volume: 17, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Male; Middle Aged; Pharmacogenetics; Psychotic Disorders; Schizophrenia

2017
Antipsychotic treatment of children and adolescents is a double-edged sword.
    The lancet. Psychiatry, 2017, Volume: 4, Issue:8

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Double-Blind Method; Humans; Psychotic Disorders; Quetiapine Fumarate

2017
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:5

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Humans; Lewy Body Disease; Male; Psychotic Disorders; Tremor

2017
Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report.
    Actas espanolas de psiquiatria, 2017, Volume: 45, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Humans; Male; Psychotic Disorders

2017
[Aripiprazole-Induced Hyperhidrosis: Two Case Reports].
    Turk psikiyatri dergisi = Turkish journal of psychiatry, 2017,Summer, Volume: 28, Issue:2

    Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Aripiprazole; Diagnosis, Differential; Female; Humans; Hyperhidrosis; Personality Disorders; Psychotic Disorders

2017
Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Cohort Studies; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Psychotic Disorders; Schizophrenia; Taiwan; Tardive Dyskinesia

2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
    European psychiatry : the journal of the Association of European Psychiatrists, 2018, Volume: 49

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Disorder, Major; Female; Humans; Incidence; Infant; Male; Mental Disorders; Norway; Olanzapine; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia

2018
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
    Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Delayed-Action Preparations; Female; Hospitalization; Humans; Inpatients; Male; Off-Label Use; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome

2018
Two-year effectiveness of risperidone and aripiprazole in the maintenance treatment of patients with recent-onset or chronic schizophrenia and related psychotic disorders: a retrospective multicenter study.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Hospitals, Psychiatric; Humans; Middle Aged; Psychotic Disorders; Retrospective Studies; Risperidone; Schizophrenia; Survival Analysis; Young Adult

2018
Can a digital medicine system improve adherence to antipsychotic treatment?
    Epidemiology and psychiatric sciences, 2018, Volume: 27, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Evidence-Based Practice; Humans; Medication Adherence; Psychotic Disorders; Telemedicine; United States; United States Food and Drug Administration

2018
Psychosis, creativity and recovery: exploring the relationship in a patient.
    BMJ case reports, 2018, Apr-26, Volume: 2018

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Creativity; Female; Humans; Medication Adherence; Paranoid Behavior; Psychotic Disorders; Recurrence; Writing

2018
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
    The American journal of psychiatry, 2018, 06-01, Volume: 175, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes, Gestational; Female; Humans; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Thiazoles; Young Adult

2018
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Human psychopharmacology, 2018, Volume: 33, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult

2018
[Evaluation of verbal inhibitory control with the Stroop Test in early episodes of psychosis with the experience of traumatic events in infancy].
    Revista de neurologia, 2018, Aug-16, Volume: 67, Issue:4

    Topics: Adolescent; Age Factors; Aripiprazole; Child; Child, Preschool; Executive Function; Female; Humans; Infant; Inhibition, Psychological; Male; Prefrontal Cortex; Psychotic Disorders; Risperidone; Stress Disorders, Traumatic; Stroop Test; Surveys and Questionnaires; Verbal Behavior

2018
Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable?
    Schizophrenia research, 2019, Volume: 204

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Hyperprolactinemia; Injections; Psychotic Disorders

2019
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:6

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult

2018
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
    Journal of child and adolescent psychopharmacology, 2019, Volume: 29, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Female; Humans; Male; Netherlands; Psychotic Disorders; Retrospective Studies; Risperidone; Time Factors; Weight Gain

2019
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
    Irish journal of medical science, 2019, Volume: 188, Issue:4

    Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 CYP2D6; Female; Humans; Hyperprolactinemia; Male; Phenotype; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult

2019
Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics.
    Journal of psychiatric practice, 2019, Volume: 25, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agents; History, 21st Century; Humans; Mental Disorders; Psychotic Disorders; Schizophrenia

2019
Editorial: Making Use of What We Know: Medical Decision-Making and Antipsychotics.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2019, Volume: 58, Issue:11

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Child; Clinical Decision-Making; Diabetes Mellitus, Type 2; Humans; Psychotic Disorders; Quetiapine Fumarate

2019
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    The lancet. Psychiatry, 2019, Volume: 6, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Male; Middle Aged; Norway; Pharmacogenomic Variants; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Failure; Young Adult

2019
Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis.
    Psychotherapy and psychosomatics, 2019, Volume: 88, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; Humans; Lamotrigine; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Treatment Outcome

2019
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
    International clinical psychopharmacology, 2013, Volume: 28, Issue:4

    Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Huntington Disease; Male; Morpholines; Piperazines; Psychotic Disorders; Quinolones; Reboxetine; Treatment Outcome

2013
Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease.
    The Journal of neuropsychiatry and clinical neurosciences, 2013,Spring, Volume: 25, Issue:2

    Topics: Antipsychotic Agents; Aripiprazole; Athetosis; Chorea; Humans; Huntington Disease; Piperazines; Psychotic Disorders; Quinolones

2013
Neurocognitive effects of aripiprazole in adolescents and young adults with schizophrenia.
    Nordic journal of psychiatry, 2014, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Cognition; Female; Humans; Male; Neuropsychological Tests; Piperazines; Prospective Studies; Psychotic Disorders; Quality of Life; Quinolones; Schizophrenia; Taiwan; Treatment Outcome; Young Adult

2014
Ceftriaxone and infection in first episode adolescent psychosis.
    Journal of child and adolescent psychopharmacology, 2013, Volume: 23, Issue:10

    Topics: Adolescent; Anti-Bacterial Agents; Aripiprazole; Bacterial Infections; Ceftriaxone; Humans; Male; Piperazines; Psychotic Disorders; Quinolones

2013
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2014, Volume: 16, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Treatment; Female; Haloperidol; Humans; Hungary; Male; Middle Aged; Olanzapine; Piperazines; Practice Patterns, Physicians'; Promethazine; Psychiatry; Psychomotor Agitation; Psychotic Disorders; Quinolones; Surveys and Questionnaires

2014
Worsening of psychosis with aripiprazole.
    The Journal of neuropsychiatry and clinical neurosciences, 2014, Apr-01, Volume: 26, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Psychotic Disorders; Quinolones

2014
Effects of antipsychotic drugs on insight in schizophrenia.
    Psychiatry research, 2014, Aug-15, Volume: 218, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles

2014
[Antipsychotics -- do they exist?].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2014, Volume: 16, Issue:2

    Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking

2014
Hiccup with aripiprazole plus benzodiazepines resolving with pregabalin and/or benzodiazepine switch/discontinuation: four case reports.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:2

    Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Calcium Channel Blockers; Hiccup; Humans; Male; Marijuana Abuse; Pregabalin; Psychoses, Substance-Induced; Psychotic Disorders; Substance-Related Disorders; Young Adult

2015
Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
    Clinical schizophrenia & related psychoses, 2016,Winter, Volume: 9, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Prolactin; Psychotic Disorders

2016
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
    Psychiatric services (Washington, D.C.), 2015, Volume: 66, Issue:6

    Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Blood Glucose; Child; Child, Preschool; Cohort Studies; Conduct Disorder; Databases, Factual; Depressive Disorder; Diabetes Mellitus; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hyperkinesis; Male; Mass Screening; Mental Disorders; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Thiazoles

2015
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Schizophrenia bulletin, 2015, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Genetic Loci; Humans; Male; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Psychotic Disorders; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Risk; Risperidone; Schizophrenia; Young Adult

2015
First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).
    Schizophrenia bulletin, 2015, Volume: 41, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Outcome Assessment, Health Care; Psychotic Disorders; Risperidone; Schizophrenia

2015
Management of aripiprazole-induced tardive Pisa syndrome: a case report and literature review.
    International clinical psychopharmacology, 2016, Volume: 31, Issue:1

    Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Case Management; Female; Humans; Movement Disorders; Psychotic Disorders; Syndrome; Treatment Outcome

2016
Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.
    BMC psychiatry, 2015, Oct-19, Volume: 15

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Movement Disorders; Neurologic Examination; Psychotic Disorders; Treatment Outcome; Young Adult

2015
Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study.
    Schizophrenia research, 2016, Volume: 170, Issue:2-3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Bipolar Disorder; Bone Remodeling; Estrogens; Female; Follow-Up Studies; Humans; Male; Middle Aged; PAX5 Transcription Factor; Prolactin; Prospective Studies; Psychotic Disorders; Schizophrenia; Sensitivity and Specificity; Testosterone; Young Adult

2016
Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
    Schizophrenia research, 2016, Volume: 174, Issue:1-3

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Energy Metabolism; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Weight Gain; Young Adult

2016
Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.
    Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Databases, Factual; Denmark; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neurodevelopmental Disorders; Obsessive-Compulsive Disorder; Psychotic Disorders; Schizophrenia; Tourette Syndrome

2016
Aripiprazole induced Impulse Control Disorders: Where do we stand?
    Asian journal of psychiatry, 2016, Volume: 23

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Young Adult

2016
Significance of findings in aripiprazole for treatment of psychoses in Alzheimer dementia.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2008, Volume: 16, Issue:7

    Topics: Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Humans; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Research Design; Treatment Outcome

2008
Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis.
    Pharmacopsychiatry, 2008, Volume: 41, Issue:4

    Topics: Adult; Aripiprazole; Female; Humans; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones

2008
Apparent commercial bias in supplement.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Bias; Commerce; Health Status; Humans; Patient Satisfaction; Piperazines; Psychopharmacology; Psychotic Disorders; Quinolones

2008
Diabetic ketoacidosis associated with aripiprazole.
    Pharmacotherapy, 2008, Volume: 28, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Diabetic Ketoacidosis; Fluid Therapy; Humans; Hypoglycemic Agents; Insulin; Male; Piperazines; Psychotic Disorders; Quinolones

2008
Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease.
    The American journal of psychiatry, 2008, Volume: 165, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones

2008
Aripiprazole treatment for depression in schizoaffective disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Dec-12, Volume: 32, Issue:8

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones

2008
Psychosis or atypical neuroleptic malignant syndrome in an adolescent?
    Journal of child and adolescent psychopharmacology, 2008, Volume: 18, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones

2008
Predictors of aripiprazole treatment continuation in hospitalized patients.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome

2008
Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome.
    Journal of psychiatric practice, 2008, Volume: 14, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Creatine Kinase; Documentation; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones

2008
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors

2009
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Psychiatry and clinical neurosciences, 2009, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult

2009
Supersensitivity psychosis after tapering aripiprazole: a case report.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Mar-17, Volume: 33, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Fear; Hallucinations; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenic Psychology

2009
Psychosis in the elderly.
    The American journal of psychiatry, 2009, Volume: 166, Issue:2

    Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride

2009
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Journal of affective disorders, 2009, Volume: 115, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome

2009
Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
    Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:2

    Topics: Amisulpride; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Biperiden; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Schizophrenic Psychology; Sulpiride; Young Adult

2009
Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Medical Records Systems, Computerized; Mental Health Services; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Schizophrenia; Severity of Illness Index

2009
Supersensitivity psychosis and aripiprazole tapering.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Jun-15, Volume: 33, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Piperazines; Psychotic Disorders; Quinolones

2009
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
    Geriatrics, 2009, Volume: 64, Issue:5

    Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Severity of Illness Index

2009
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia

2009
Aripiprazole treatment of psychosis in a child with posterior fossa retrocerebellar arachnoid cyst.
    Journal of child and adolescent psychopharmacology, 2009, Volume: 19, Issue:3

    Topics: Antipsychotic Agents; Arachnoid Cysts; Aripiprazole; Child; Cranial Fossa, Posterior; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Radiography

2009
Reversible Pisa syndrome associated with switching from haloperidol to aripiprazole during lithium treatment.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Oct-01, Volume: 33, Issue:7

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chloroquinolinols; Dystonia; Female; Humans; Lithium Compounds; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Spasm

2009
Tardive dyskinesia in a patient treated with quetiapine.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:1

    Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles

2009
Serious generalized tonic-clonic seizures induced by aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Feb-01, Volume: 34, Issue:1

    Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Humans; Male; Phenytoin; Piperazines; Psychotic Disorders; Quinolones; Seizures

2010
Aripiprazole and hypertension in adolescents.
    Journal of child and adolescent psychopharmacology, 2009, Volume: 19, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Calcium Channel Blockers; Female; Humans; Hypertension; Nifedipine; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index

2009
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine.
    Journal of psychiatric practice, 2009, Volume: 15, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Carbamazepine; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Male; Medical Audit; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk Factors; Risperidone

2009
The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.
    Clinical therapeutics, 2010, Volume: 32 Suppl 1

    Topics: Antipsychotic Agents; Aripiprazole; Canada; Clinical Trials as Topic; Comorbidity; Drug Utilization; Drug Utilization Review; Humans; Metabolic Diseases; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Risk Factors

2010
Symptomatic bradycardia with oral aripiprazole and oral ziprasidone.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:4

    Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bradycardia; Delusions; Electrocardiography; Female; Humans; Lithium Carbonate; Piperazines; Psychotic Disorders; Quinolones; Thiazoles

2010
Hyperprolactinaemia during treatment with paliperidone.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2010, Volume: 18, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult

2010
Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome

2010
Treatment of schizophreniform disorder by aripiprazole in a female adolescent with 22q11.2 deletion syndrome.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Aug-16, Volume: 34, Issue:6

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; DiGeorge Syndrome; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2010
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.
    Pharmacopsychiatry, 2010, Volume: 43, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Memory Disorders; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2010
Antipsychotic dosing: still a work in progress.
    The American journal of psychiatry, 2010, Volume: 167, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Severity of Illness Index

2010
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
    The Journal of neuropsychiatry and clinical neurosciences, 2010,Summer, Volume: 22, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome

2010
Aripiprazole can treat psychotic features but not motor symptoms of Parkinson's disease: evidence from a SPECT study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Protein Binding; Psychotic Disorders; Quinolones; Tomography, Emission-Computed, Single-Photon

2011
Worsening psychosis after adding aripiprazole to clozapine.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Piperazines; Psychotic Disorders; Quinolones

2011
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
    Schizophrenia research, 2011, Volume: 125, Issue:2-3

    Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3

2011
Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.
    Psychopharmacology bulletin, 2010, Volume: 43, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Labeling; Drug Resistance; Female; Humans; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2010
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
    Schizophrenia bulletin, 2012, Volume: 38, Issue:4

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2012
Aripiprazole associated hyponatraemia.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:8

    Topics: Aripiprazole; Female; Humans; Hyponatremia; Middle Aged; Piperazines; Psychotic Disorders; Quinolones

2011
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
    Journal of psychiatric practice, 2011, Volume: 17, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain

2011
Switching antipsychotic medications: not enough, too often, or just right?
    The American journal of psychiatry, 2011, Volume: 168, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia

2011
Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:9

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depression; Dystonia; Female; Fluoxetine; Humans; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones

2012
Cerebral blood flow changes in very-late-onset schizophrenia-like psychosis with catatonia before and after successful treatment.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:6

    Topics: Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Catatonia; Cerebrovascular Circulation; Female; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2011
Aripiprazole monotherapy in the treatment of vascular parkinsonism.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:6

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Parkinson Disease, Secondary; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2011
Intermittent aripiprazole for schizophrenia.
    Schizophrenia research, 2012, Volume: 134, Issue:2-3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia

2012
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
    International journal of psychiatry in clinical practice, 2012, Volume: 16, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol; Humans; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Recurrence; Risperidone

2012
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
    Gender medicine, 2012, Volume: 9, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia

2012
Emergence of psychotic symptoms during Internet withdrawal.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:2

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Behavior, Addictive; Humans; Internet; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2012
Factors influencing the adherence of antipsychotic medication (Aripiprazole) in first-episode psychosis: findings from a grounded theory study.
    Journal of psychiatric and mental health nursing, 2012, Volume: 19, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Data Collection; Disability Evaluation; England; Female; Health Status; Humans; Interview, Psychological; Male; Medication Adherence; Nursing Theory; Patient Participation; Piperazines; Psychotic Disorders; Quality of Life; Quinolones; Young Adult

2012
Is there a role for loading dose regimes in aripiprazole therapy?
    The Australian and New Zealand journal of psychiatry, 2012, Volume: 46, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones

2012
Graves' hyperthyroidism-induced psychosis treated with aripiprazole--a case report.
    Journal of pharmacy practice, 2013, Volume: 26, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Graves Disease; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones

2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jan-10, Volume: 40

    Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain

2013
Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult

2013
Aripiprazole-related severe neuroleptic malignant syndrome with deep coma and organic brain changes in an antipsychotic-naive adolescent boy.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:1

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Brain; Coma; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Predictive Value of Tests; Psychotic Disorders; Quinolones; Treatment Outcome

2013
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Electroencephalography; Evoked Potentials; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Young Adult

2013
Aripiprazole-induced improvement in tardive dyskinesia.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index

2003
Aripiprazole possibly worsens psychosis.
    International clinical psychopharmacology, 2004, Volume: 19, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2

2004
Worsening schizoaffective disorder with aripiprazole.
    The American journal of psychiatry, 2004, Volume: 161, Issue:7

    Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones

2004
Possible increased efficacy of low-dose clozapine when combined with aripiprazole.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:9

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Treatment Outcome

2004
Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
    CNS spectrums, 2004, Volume: 9, Issue:11

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia

2004
Aripiprazole-associated dyskinesia.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones

2005
Pharmacokinetics of aripiprazole and concomitant lithium and valproate.
    Journal of clinical pharmacology, 2005, Volume: 45, Issue:1

    Topics: Adult; Aripiprazole; Drug Therapy, Combination; Humans; Lithium; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Valproic Acid

2005
The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.
    Journal of child and adolescent psychopharmacology, 2004,Winter, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome

2004
Aripiprazole and depression in schizoaffective disorder.
    The American journal of psychiatry, 2005, Volume: 162, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Comorbidity; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2005
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2005
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
    Journal of psychiatric practice, 2005, Volume: 11, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome

2005
Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Clozapine; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Piperazines; Psychotic Disorders; Quinolones

2005
Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole.
    Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Anxiety Agents; Anti-HIV Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Lorazepam; Male; Piperazines; Psychotic Disorders; Quinolones

2005
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2005
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
    Nederlands tijdschrift voor geneeskunde, 2005, Oct-08, Volume: 149, Issue:41

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Suicide, Attempted; Thinking

2005
Galactorrhea with aripiprazole.
    Psychotherapy and psychosomatics, 2005, Volume: 74, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Piperazines; Psychotic Disorders; Quinolones

2005
Use of aripiprazole for psychosis and agitation in dementia.
    International psychogeriatrics, 2006, Volume: 18, Issue:2

    Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Female; Humans; Neuropsychological Tests; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Treatment Outcome

2006
Treatment-emergent psychosis with aripiprazole.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones

2005
Atypical antipsychotics: special formulations for acute agitation.
    Journal of psychosocial nursing and mental health services, 2005, Volume: 43, Issue:10

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Risperidone; Thiazoles

2005
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
    Journal of neurology, 2006, Volume: 253, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diet; Epilepsy, Generalized; Female; Hallucinations; Humans; Hypnotics and Sedatives; Hypothyroidism; Lorazepam; Magnetic Resonance Imaging; Multiple Sclerosis; Paranoid Disorders; Piperazines; Psychotic Disorders; Quinolones

2006
Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder.
    The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:2

    Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Psychotic Disorders; Quinolones

2006
Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole.
    The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Schizophrenia; Serotonin Agents; Treatment Outcome

2007
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
    Nederlands tijdschrift voor geneeskunde, 2006, Feb-18, Volume: 150, Issue:7

    Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted

2006
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
    Nederlands tijdschrift voor geneeskunde, 2006, Feb-18, Volume: 150, Issue:7

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quinolones; Sleep Wake Disorders; Suicide, Attempted

2006
The acutely psychotic patient--assessment and initial management.
    Australian family physician, 2006, Volume: 35, Issue:3

    Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Cyclohexanols; Female; Humans; Male; Physicians, Family; Piperazines; Practice Guidelines as Topic; Psychotic Disorders; Quinolones; Referral and Consultation; Risk Assessment; Venlafaxine Hydrochloride

2006
Benefits of combining aripiprazole to clozapine: three case reports.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Aug-30, Volume: 30, Issue:6

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia, Disorganized; Schizophrenia, Paranoid

2006
Clozapine augmentation with aripiprazole for negative symptoms.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:4

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome

2006
Aripiprazole use in a pregnant schizoaffective woman.
    Bipolar disorders, 2006, Volume: 8, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Lactation; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quinolones

2006
Aripiprazole associated with severe exacerbation of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones

2006
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
    Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:6

    Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid

2006
Neuroacanthocytosis: presenting with depression.
    The Journal of neuropsychiatry and clinical neurosciences, 2006,Summer, Volume: 18, Issue:3

    Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dystonia; Female; Humans; Piperazines; Psychotic Disorders; Quinolones

2006
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Severity of Illness Index; Time Factors

2006
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:7

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; Catalepsy; Clozapine; Dopamine Agonists; Drug Evaluation, Preclinical; Haloperidol; Male; Piperazines; Prolactin; Proto-Oncogene Proteins c-fos; Psychotic Disorders; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Treatment Outcome

2007
Psychosis in a patient with Fabry's disease and treatment with aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2007, Apr-13, Volume: 31, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Fabry Disease; Humans; Male; Piperazines; Psychotic Disorders; Quinolones

2007
Diagnostic and therapeutic challenges in narcolepsy-related psychosis.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Female; Hallucinations; Humans; Narcolepsy; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia

2006
Manic episode during treatment with aripiprazole.
    The American journal of psychiatry, 2007, Volume: 164, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones

2007
Datapoints: The ups and downs of dosing second-generation antipsychotics.
    Psychiatric services (Washington, D.C.), 2007, Volume: 58, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles

2007
Aripiprazole in human milk.
    The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:3

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Milk, Human; Piperazines; Psychotic Disorders; Quinolones

2007
Aripiprazole and neuroleptic malignant syndrome.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones

2007
Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis.
    Journal of psychiatric practice, 2007, Volume: 13, Issue:2

    Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examination; Piperazines; Psychotic Disorders; Quinolones

2007
Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Carbamazepine; Female; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychotic Disorders; Quinolones; Trifluoperazine

2007
Augmentation of clozapine treatment with aripiprazole.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2007
Aripiprazole and worsening of psychosis: a case report.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:5

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Disease Progression; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Recurrence

2007
Psychotic episode associated with Bikram yoga.
    The American journal of psychiatry, 2007, Volume: 164, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Yoga

2007
Successful treatment of catatonia with aripiprazole in an adolescent with psychosis.
    Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Child Development Disorders, Pervasive; Child, Preschool; Female; Hospitalization; Humans; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones

2007
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.
    Eating and weight disorders : EWD, 2007, Volume: 12, Issue:3

    Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Comorbidity; Epilepsy; Female; Humans; Kidney Failure, Chronic; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2007
Aripiprazole: effectiveness and safety under naturalistic conditions.
    Experimental and clinical psychopharmacology, 2007, Volume: 15, Issue:6

    Topics: Adult; Antipsychotic Agents; Anxiety; Aripiprazole; Female; Humans; Inpatients; Italy; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Recurrence; Retrospective Studies; Schizoid Personality Disorder; Schizophrenia, Paranoid; Schizotypal Personality Disorder; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome

2007
Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis.
    Brain injury, 2008, Volume: 22, Issue:1

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain Injuries; Dyskinesia, Drug-Induced; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome; Withholding Treatment

2008
Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:3

    Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Blood Cell Count; Dibenzothiazepines; Female; Humans; Leukopenia; Neutropenia; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride

2008
Change in sexual dysfunction with aripiprazole: a switching or add-on study.
    Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Ejaculation; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Libido; Male; Menstruation Disturbances; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Sex Characteristics; Sexual Dysfunction, Physiological; Surveys and Questionnaires

2008
Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dystonia; Humans; Male; Piperazines; Psychotic Disorders; Quinolones

2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors

2008
Do dopamine partial agonists have partial efficacy as antipsychotics?
    CNS spectrums, 2008, Volume: 13, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Brain; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Treatment Outcome

2008
Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3

    Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Parkinsonian Disorders; Piperazines; Polymorphism, Genetic; Psychotic Disorders; Quinolones; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risk Factors

2008
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Binding Sites; Corpus Striatum; Dopamine Agents; Humans; Piperazines; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Substantia Nigra

2001